• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CTNNB1 在子宫内膜癌中的作用。

The Role of CTNNB1 in Endometrial Cancer.

机构信息

Department of Pathology, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia.

Divison for Gynaecology and Perinatology, University Medical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia.

出版信息

Dis Markers. 2022 Apr 28;2022:1442441. doi: 10.1155/2022/1442441. eCollection 2022.

DOI:10.1155/2022/1442441
PMID:35531470
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9072012/
Abstract

Endometrial cancer (EC) is the most common gynaecologic malignancy in the developed countries. Recent evidence suggests that histopathological subtyping together with molecular subgrouping can lead to more accurate assessment of the risk profile for the patient. Clinical studies suggest the currently used molecular classification improves the risk assessment of women with endometrial cancer but does not explain the differences in recurrence profiles clearly. This could be improved by novel markers. One of such are mutations in the -catenin () gene, a frequently mutated gene in endometrial cancer. This shows mutations mostly at phosphorylation sites of the -catenin and almost exclusively in the endometrial subgroup of no specific molecular profile. mutations lead to alterations in the Wnt/-catenin signalling pathway, involved in the carcinogenesis and progression of EC by inducing transcription of target genes, whose function is to regulate the cell cycle. Although tumours with mutations in tend to have low-risk characteristics, they are related to worse outcomes with significantly increased rate of disease recurrence and lower overall survival.

摘要

子宫内膜癌(EC)是发达国家最常见的妇科恶性肿瘤。最近的证据表明,组织病理学亚型与分子亚群相结合可以更准确地评估患者的风险状况。临床研究表明,目前使用的分子分类可以提高子宫内膜癌患者的风险评估,但不能清楚地解释复发模式的差异。这可以通过新的标志物来改善。其中之一是 -连环蛋白()基因的突变,该基因在子宫内膜癌中经常发生突变。这表明突变主要发生在 -连环蛋白的磷酸化位点,几乎仅在无特定分子特征的子宫内膜亚组中发生。 突变导致 Wnt/-连环蛋白信号通路的改变,通过诱导靶基因的转录,参与 EC 的发生和进展,靶基因的功能是调节细胞周期。尽管 -连环蛋白基因突变的肿瘤往往具有低风险特征,但它们与更差的结果相关,疾病复发率显著增加,总生存率降低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4631/9072012/650fb4c2d7db/DM2022-1442441.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4631/9072012/6710bcf85afc/DM2022-1442441.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4631/9072012/1daf38368f08/DM2022-1442441.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4631/9072012/cb36db310c50/DM2022-1442441.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4631/9072012/650fb4c2d7db/DM2022-1442441.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4631/9072012/6710bcf85afc/DM2022-1442441.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4631/9072012/1daf38368f08/DM2022-1442441.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4631/9072012/cb36db310c50/DM2022-1442441.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4631/9072012/650fb4c2d7db/DM2022-1442441.004.jpg

相似文献

1
The Role of CTNNB1 in Endometrial Cancer.CTNNB1 在子宫内膜癌中的作用。
Dis Markers. 2022 Apr 28;2022:1442441. doi: 10.1155/2022/1442441. eCollection 2022.
2
Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer.抑制 CTNNB1 突变型子宫内膜癌中的 Wnt/β-连环蛋白。
Mol Carcinog. 2021 Aug;60(8):511-523. doi: 10.1002/mc.23308. Epub 2021 May 26.
3
Early-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence.早期子宫内膜癌、CTNNB1 突变与淋巴管血管间隙浸润和复发的关系。
Acta Obstet Gynecol Scand. 2020 Feb;99(2):196-203. doi: 10.1111/aogs.13740. Epub 2019 Nov 7.
4
Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.CTNNB1 突变在低级别、早期子宫内膜样型子宫内膜癌中的临床病理特征和预后意义。
Virchows Arch. 2021 Dec;479(6):1167-1176. doi: 10.1007/s00428-021-03176-5. Epub 2021 Aug 21.
5
Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.CTNNB1 突变和 Wnt 通路激活在子宫内膜样型子宫内膜癌中的临床意义。
J Natl Cancer Inst. 2014 Sep 10;106(9). doi: 10.1093/jnci/dju245. Print 2014 Sep.
6
Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.CTNNB1 突变的子宫内膜样癌的临床病理与免疫组化相关性
Int J Gynecol Pathol. 2020 Mar;39(2):119-127. doi: 10.1097/PGP.0000000000000583.
7
Long non-coding RNA steroid receptor activator promotes the progression of endometrial cancer via Wnt/ β-catenin signaling pathway.长非编码 RNA 甾体受体激活物通过 Wnt/β-连环蛋白信号通路促进子宫内膜癌的进展。
Int J Biol Sci. 2020 Jan 1;16(1):99-115. doi: 10.7150/ijbs.35643. eCollection 2020.
8
Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.复发性 I 期、1 级子宫内膜样腺癌的分子标志物。
Gynecol Oncol. 2019 Jun;153(3):517-520. doi: 10.1016/j.ygyno.2019.03.100. Epub 2019 Mar 22.
9
The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.CTNNB1 突变和基质金属蛋白酶 (MMPs) 在子宫内膜癌抗血管生成治疗中的作用。
Gynecol Oncol. 2022 Nov;167(2):323-333. doi: 10.1016/j.ygyno.2022.09.013. Epub 2022 Sep 21.
10
Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer.Sox7的下调与子宫内膜癌中Wnt/β-连环蛋白信号通路的异常激活有关。
Oncotarget. 2012 Dec;3(12):1546-56. doi: 10.18632/oncotarget.667.

引用本文的文献

1
Therapeutic Potential of Glucose Oxidase-Loaded Biogenic Mesoporous Silica Nanoparticles in Ovarian Cancer.负载葡萄糖氧化酶的生物源介孔二氧化硅纳米颗粒在卵巢癌中的治疗潜力
Pharmaceuticals (Basel). 2025 Jul 18;18(7):1060. doi: 10.3390/ph18071060.
2
Angio-associated migratory cell protein promotes colorectal cancer progression by enhancing phosphoglycerate kinase 1 phosphorylation.血管相关迁移细胞蛋白通过增强磷酸甘油酸激酶1磷酸化促进结直肠癌进展。
J Cell Commun Signal. 2025 Jun 16;19(2):e70023. doi: 10.1002/ccs3.70023. eCollection 2025 Jun.
3
Differential Localization of β-Catenin Protein in CTNNB1 Mutant Endometrial Cancers Results in Distinct Transcriptional Profiles.

本文引用的文献

1
Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience.子宫内膜癌的前瞻性分子分类:机构实施、实践与临床经验
Mod Pathol. 2022 May;35(5):688-696. doi: 10.1038/s41379-021-00963-y. Epub 2021 Nov 6.
2
Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment.早期子宫内膜癌的辅助治疗建议:基于整合分子风险评估的引入有哪些变化。
Front Oncol. 2021 Sep 1;11:612450. doi: 10.3389/fonc.2021.612450. eCollection 2021.
3
Pre-treatment risk assessment of women with endometrial cancer: differences in outcomes of molecular and clinical classifications in the Slovenian patient cohort.
β-连环蛋白在CTNNB1突变型子宫内膜癌中的差异定位导致不同的转录谱。
Mod Pathol. 2025 May 8;38(9):100791. doi: 10.1016/j.modpat.2025.100791.
4
Identification of key pathways and molecular players potentially involved in endometrial cancer metastasis through integrated bioinformatics analyses.通过综合生物信息学分析鉴定可能参与子宫内膜癌转移的关键途径和分子参与者。
Bioimpacts. 2024 Jun 26;15:30222. doi: 10.34172/bi.30222. eCollection 2025.
5
The genomic landscape of distant metastatic endometrial cancer.远处转移性子宫内膜癌的基因组格局
Gynecol Oncol. 2025 Apr;195:89-97. doi: 10.1016/j.ygyno.2025.03.006. Epub 2025 Mar 12.
6
The Histomorphology to Molecular Transition: Exploring the Genomic Landscape of Poorly Differentiated Epithelial Endometrial Cancers.从组织形态学到分子转变:探索低分化子宫内膜上皮癌的基因组格局
Cells. 2025 Mar 5;14(5):382. doi: 10.3390/cells14050382.
7
MRPL24 drives breast cancer metastasis and stemness by targeting c-MYC, BRD4, and STAT3.MRPL24通过靶向c-MYC、BRD4和STAT3驱动乳腺癌转移和干性。
3 Biotech. 2025 Feb;15(2):37. doi: 10.1007/s13205-024-04196-z. Epub 2025 Jan 9.
8
Detection of driver mutations and genomic signatures in endometrial cancers using artificial intelligence algorithms.利用人工智能算法检测子宫内膜癌中的驱动基因突变和基因组特征。
PLoS One. 2024 Feb 26;19(2):e0299114. doi: 10.1371/journal.pone.0299114. eCollection 2024.
9
Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate β-Catenin Signaling.分析肿瘤相关 AXIN1 错义突变,鉴定激活 β-连环蛋白信号的变异体。
Cancer Res. 2024 May 2;84(9):1443-1459. doi: 10.1158/0008-5472.CAN-23-2268.
10
Cannflavins A and B with Anti-Ferroptosis, Anti-Glycation, and Antioxidant Activities Protect Human Keratinocytes in a Cell Death Model with Erastin and Reactive Carbonyl Species.具有抗铁死亡、抗糖化和抗氧化活性的 Cannflavins A 和 B 通过 Erastin 和活性羰基物种保护人角质形成细胞免于细胞死亡模型。
Nutrients. 2023 Oct 27;15(21):4565. doi: 10.3390/nu15214565.
子宫内膜癌患者的术前风险评估:斯洛文尼亚患者队列中分子和临床分类的结局差异。
Radiol Oncol. 2021 Sep 17;56(1):76-82. doi: 10.2478/raon-2021-0036.
4
Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.CTNNB1 突变在低级别、早期子宫内膜样型子宫内膜癌中的临床病理特征和预后意义。
Virchows Arch. 2021 Dec;479(6):1167-1176. doi: 10.1007/s00428-021-03176-5. Epub 2021 Aug 21.
5
Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.2021 年分子 ESGO/ESTRO/ESP 风险组在子宫内膜癌中的应用。
Gynecol Oncol. 2021 Aug;162(2):394-400. doi: 10.1016/j.ygyno.2021.05.026. Epub 2021 Jun 11.
6
New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines.基于更新后的ESGO/ESTRO/ESP指南看子宫内膜癌的新病理及临床见解
Cancers (Basel). 2021 May 26;13(11):2623. doi: 10.3390/cancers13112623.
7
Targeting Wnt Signaling in Endometrial Cancer.靶向子宫内膜癌中的Wnt信号通路
Cancers (Basel). 2021 May 13;13(10):2351. doi: 10.3390/cancers13102351.
8
Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer.抑制 CTNNB1 突变型子宫内膜癌中的 Wnt/β-连环蛋白。
Mol Carcinog. 2021 Aug;60(8):511-523. doi: 10.1002/mc.23308. Epub 2021 May 26.
9
Trends in population-based cancer survival in Slovenia.斯洛文尼亚基于人群的癌症生存趋势。
Radiol Oncol. 2021 Jan 21;55(1):42-49. doi: 10.2478/raon-2021-0003.
10
Cancer statistics for the year 2020: An overview.2020年癌症统计数据概述。
Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588.